Gastroparesis is a condition in which the stomach empties too slowly—causing nausea, vomiting, bloating, and pain. It's often associated with diabetes but can occur for other reasons. Treatment focuses on symptom relief and improving gastric motility, and the gastroparesis drugs market reflects this clinical need.

The Gastroparesis Drugs Market was valued at approximately USD 4.931 billion in 2024 and is projected to reach USD 8.767 billion by 2035, growing at a CAGR of about 5.37%. Growth is driven by rising prevalence, increasing awareness, and drug development. North America leads; Asia-Pacific grows fastest.

The market is segmented by drug type (prokinetic agents—largest; anti-emetics—fastest-growing), by route (oral—largest; injectable—fastest-growing), by patient type (adults—largest; pediatric—fastest-growing), and by application (symptom management—largest; disease management—fastest-growing).

The competitive landscape includes AbbVie, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, Sanofi, Takeda, and Teva, with recent developments including new FDA approvals.

Looking ahead, personalized medicine, new prokinetics, and drug delivery innovation will shape competition. For stakeholders, efficacy and safety are keys to success.

People Also Ask

What is gastroparesis?
It's delayed stomach emptying—causing nausea, vomiting, and bloating.

What drugs treat gastroparesis?
Prokinetic agents, anti-emetics, and other medications—treatment focuses on symptoms.

Tags

#Gastroparesis #GastroparesisDrugs #Prokinetics #GIHealth #DiabetesComplications #Gastroenterology